Skip to main content

Advertisement

Table 2 Discontinuation and adverse events of prophylactic micafungin during first induction chemotherapy

From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

  Number of patients (%)
Incidence of fungal infection 3/65 (4.6)
 Proven fungal infection 1/65 (1.5)
 Probable fungal infection 0
 Possible fungal infection 2/65 (3.1)
Discontinuation of prophylactic micafungin 19/65 (29.2)
 Cause of discontinuation
  Suspected fungal infections 3/65 (4.6)
  Prolonged neutropenic fever 14/65 (21.5)
  Adverse events 2/65 (3.1)
Micafungin treatment completed 46/65 (70.8)
Switch to another antifungal agent 18/65 (27.7)
Adverse events related to micafungin 3/65 (4.6)
 Liver function test abnormality 2/65 (3.1)
  Grade 2 1/65 (1.5)
  Grade 3 1/65 (1.5)
 Allergic reaction 1/65 (1.5)
  Grade 2 1/65 (1.5)
 No adverse event 62/65 (95.4)
Cause of mortality during induction chemotherapy 3/65 (4.6)
 Fungal infection (proven) 1/65 (1.5)
 Respiratory failure (pneumonia and pulmonary edema) 1/65 (1.5)
 Septic shock 1/65 (1.5)